Efficacy of quetiapine in the treatment of behavioral symptoms in dementia

Onor, Maria Luisa; Saina, M.; Vanna, Maurizio De; Aguglia, Eugenio

doi:10.1016/s0924-9338(02)80580-6

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Quetiapine is a true “atypical” antipsychotic with even lower D2 binding affinity than clozapine. Several open‐label reports have suggested that it could be effective against hallucinations associated with dopaminergic medications 29–35…”

mentioning

confidence: 99%

Double‐blind, placebo‐controlled, unforced titration parallel trial of quetiapine for dopaminergic‐induced hallucinations in Parkinson's disease

et al. 2005

View full text Add to dashboard Cite

We completed a single site, double-blind, placebo-controlled, parallel design study of quetiapine for hallucinations in PD. Thirty-one subjects with PD and prominent visual hallucinations and Mini-Mental State Examination score >21 were randomly assigned in a 2:1 drug to placebo ratio, up to 200 mg daily of quetiapine or matching placebo given in two doses. They were seen at 3 weeks (100 mg/day) and 12 weeks (200 mg/day, with optional dose reduction). Evaluation included the Unified Parkinson's Disease Rating Scale (UPDRS), the Baylor PD Hallucination Questionnaire, and a battery of neuropsychological tests. The demographics between subjects randomized to drug (n = 21) vs. placebo (n = 10) were similar. The final dose of active drug was 200 (n = 11), 150 (n = 2), 100 (n = 3), and 75 (n = 1) mg per day. All placebo subjects were on the equivalent of 200 mg per day. The UPDRS Activities of Daily Living and Motor scores did not significantly change compared to placebo. Compared to placebo, there were no significant changes in our hallucination questionnaire, the Brief Psychiatric Rating Scale (BPRS), or question 12 (hallucination item) of the BPRS. There were no significant changes on any of the neuropsychological measures. Adverse events on drug included sedation (n = 9), but no drug-related adverse events precipitated discontinuation and none were rated as serious. Quetiapine, up to 200 mg daily, was well tolerated and did not worsen UPDRS scores; however, there was no significant improvement in psychosis rating scales compared to placebo. Larger doses of drug and greater sample sizes might be considered in future studies.

show abstract

mentioning

confidence: 99%

Double‐blind, placebo‐controlled, unforced titration parallel trial of quetiapine for dopaminergic‐induced hallucinations in Parkinson's disease

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Recently, atypical antipsychotic agents that have low incidences of adverse effects, such as respiridone 6 and olanzapine, 7 have become available, and their use in elderly patients is anticipated. Quetiapine, which is one such drug, has been reported to be effective for psychotic symptoms associated with dementia and psychiatric disorders in the elderly 8,9 . In previous reports, the total daily dose of quetiapine was 50–400 mg/day and the duration of exposure was 56–87 days.…”

Section: Introductionmentioning

confidence: 99%

“…Que-tiapine, which is one such drug, has been reported to be effective for psychotic symptoms associated with dementia and psychiatric disorders in the elderly. 8,9 In previous reports, the total daily dose of quetiapine was 50-400 mg/day and the duration of exposure was 56-87 days. In this paper, we report the use of low doses of quetiapine to control psychotic symptoms in elderly patients with physical illnesses.…”

Section: Introductionmentioning

confidence: 99%

Effects of low‐dose quetiapine on psychotic symptoms in elderly patients with physical illnesses: Report of eight cases

et al. 2003

View full text Add to dashboard Cite

Quetiapine, which is a new atypical antipsychotic agent, was administered at low doses (25–50 mg/day) for psychotic symptoms in eight elderly patients with physical illnesses. Delirium and hallucination were alleviated by the administration of low doses of quetiapine, and the cause–effect relationship between the administration and alleviation of symptoms was evident, particularly in one patient with delirium, because delirium was alleviated after administration began, was exacerbated after discontinuation of quetiapine, and was alleviated again after administration was resumed. Little improvement was observed in delusions or mood disorders. None of the patients showed exacerbation of physical symptoms or abnormalities in clinical laboratory tests. The results of this study suggest that quetiapine might be effective in reducing delirium and hallucination that often accompany physical illness in elderly people and could be used without adverse effects.

show abstract

Efficacy of quetiapine in the treatment of behavioral symptoms in dementia

Cited by 2 publications

References 0 publications

Double‐blind, placebo‐controlled, unforced titration parallel trial of quetiapine for dopaminergic‐induced hallucinations in Parkinson's disease

Double‐blind, placebo‐controlled, unforced titration parallel trial of quetiapine for dopaminergic‐induced hallucinations in Parkinson's disease

Effects of low‐dose quetiapine on psychotic symptoms in elderly patients with physical illnesses: Report of eight cases

Contact Info

Product

Resources

About